Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nalpropion Pharmaceuticals Inc. operates in the Biotechnology & Pharmaceuticals sector and currently has 1 pending office action. Prosecution is handled by a distinct examiner and 1 distinct art unit. This concentration suggests a streamlined approach to the company's active patent filings.
The busiest examiner is YU, HONG, who is currently overseeing the pending office action. This examiner is responsible for the portfolio's entire active workload, as the total number of pending office actions is limited. The presence of 1 distinct art unit indicates that the pending matter is being reviewed within a specialized division.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, HONG | 1 | 31.1% | +5.8% |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNalpropion Pharmaceuticals Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Hong Yu has the most, with 1 of Nalpropion Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.